{"pmid":32356761,"title":"Navigating the Pandemic Response Life Cycle: Molecular Diagnostics and Immunoassays in the Context of COVID-19 Management.","text":["Navigating the Pandemic Response Life Cycle: Molecular Diagnostics and Immunoassays in the Context of COVID-19 Management.","Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To counter COVID-19 spreading, an infrastructure to provide rapid and thorough molecular diagnostics and serology testing is the cornerstone of outbreak and pandemic management. We hereby review the clinical insights with regard to using molecular tests and immunoassays in the context of COVID-19 management life cycle: the preventive phase, the preparedness phase, the response phase and the recovery phase. The spatial and temporal distribution of viral RNA, antigens and antibodies during human infection is summarized to provide a biological foundation for accurate detection of the disease. We shared the lessons learned and the obstacles encountered during real world high-volume screening programs. Clinical needs are discussed to identify existing technology gaps in these tests. Leverage technologies, such as engineered polymerases, isothermal amplification, and direct amplification from complex matrices may improve the productivity of current infrastructure, while emerging technologies like CRISPR diagnostics, visual end point detection, and PCR free methods for nucleic acid sensing may lead to at-home tests. The lessons learned, and innovations spurred from the COVID-19 pandemic could upgrade our global public health infrastructure to better combat potential outbreaks in the future.","IEEE Rev Biomed Eng","Zhang, Jingwei","Gharizadeh, Baback","Lu, Daru","Yue, Junqiu","Yu, Mingxia","Liu, Yue","Zhou, Meiying","32356761"],"abstract":["Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To counter COVID-19 spreading, an infrastructure to provide rapid and thorough molecular diagnostics and serology testing is the cornerstone of outbreak and pandemic management. We hereby review the clinical insights with regard to using molecular tests and immunoassays in the context of COVID-19 management life cycle: the preventive phase, the preparedness phase, the response phase and the recovery phase. The spatial and temporal distribution of viral RNA, antigens and antibodies during human infection is summarized to provide a biological foundation for accurate detection of the disease. We shared the lessons learned and the obstacles encountered during real world high-volume screening programs. Clinical needs are discussed to identify existing technology gaps in these tests. Leverage technologies, such as engineered polymerases, isothermal amplification, and direct amplification from complex matrices may improve the productivity of current infrastructure, while emerging technologies like CRISPR diagnostics, visual end point detection, and PCR free methods for nucleic acid sensing may lead to at-home tests. The lessons learned, and innovations spurred from the COVID-19 pandemic could upgrade our global public health infrastructure to better combat potential outbreaks in the future."],"journal":"IEEE Rev Biomed Eng","authors":["Zhang, Jingwei","Gharizadeh, Baback","Lu, Daru","Yue, Junqiu","Yu, Mingxia","Liu, Yue","Zhou, Meiying"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356761","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1109/RBME.2020.2991444","topics":["Diagnosis"],"weight":1,"_version_":1666138495180079105,"score":9.490897,"similar":[{"pmid":32367615,"title":"Trends and innovations in biosensors for COVID-19 mass testing.","text":["Trends and innovations in biosensors for COVID-19 mass testing.","Fast and widespread diagnosis is crucial to fight against the outbreak of COVID-19. The present work surveys the landscape of available and emerging biosensor technologies for COVID-19 testing. Molecular diagnostic assays based on quantitative Reverse Transcription Polymerase Chain Reaction are used in most clinical laboratories. The COVID-19 pandemic has overwhelmed the testing capacity and motivated the development of fast point-of-care tests and the adoption of isothermal DNA amplification. Antigenic and serological rapid tests based on lateral flow immunoassays suffer from low sensitivity. Advanced digital systems enhance the performance at the expense of speed and large equipment requirement. Emerging technologies, including CRISPR gene-editing tools, benefit from high sensitivity and selectivity of molecular diagnostics and the easy use of lateral flow assays. DNA sequencing and sample pooling strategies are highlighted to bring out the full capacity of the available biosensor technologies and accelerate mass testing.","Chembiochem","Santiago, Ibon","32367615"],"abstract":["Fast and widespread diagnosis is crucial to fight against the outbreak of COVID-19. The present work surveys the landscape of available and emerging biosensor technologies for COVID-19 testing. Molecular diagnostic assays based on quantitative Reverse Transcription Polymerase Chain Reaction are used in most clinical laboratories. The COVID-19 pandemic has overwhelmed the testing capacity and motivated the development of fast point-of-care tests and the adoption of isothermal DNA amplification. Antigenic and serological rapid tests based on lateral flow immunoassays suffer from low sensitivity. Advanced digital systems enhance the performance at the expense of speed and large equipment requirement. Emerging technologies, including CRISPR gene-editing tools, benefit from high sensitivity and selectivity of molecular diagnostics and the easy use of lateral flow assays. DNA sequencing and sample pooling strategies are highlighted to bring out the full capacity of the available biosensor technologies and accelerate mass testing."],"journal":"Chembiochem","authors":["Santiago, Ibon"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32367615","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/cbic.202000250","keywords":["covid-19","crispr diagnostics","immunoassays","isothermal amplification","molecular diagnostics"],"topics":["Diagnosis"],"weight":1,"_version_":1666138496268500992,"score":223.993},{"pmid":32282894,"pmcid":"PMC7170415","title":"Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review.","text":["Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review.","Diagnostic testing to identify persons infected with severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) infection is central to control the global pandemic of COVID-19 that began in late 2019. In a few countries, the use of diagnostic testing on a massive scale has been a cornerstone of successful containment strategies. In contrast, the United States, hampered by limited testing capacity, has prioritized testing for specific groups of persons. Real-time reverse transcriptase polymerase chain reaction-based assays performed in a laboratory on respiratory specimens are the reference standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging. Although excellent tools exist for the diagnosis of symptomatic patients in well-equipped laboratories, important gaps remain in screening asymptomatic persons in the incubation phase, as well as in the accurate determination of live viral shedding during convalescence to inform decisions to end isolation. Many affluent countries have encountered challenges in test delivery and specimen collection that have inhibited rapid increases in testing capacity. These challenges may be even greater in low-resource settings. Urgent clinical and public health needs currently drive an unprecedented global effort to increase testing capacity for SARS-CoV-2 infection. Here, the authors review the current array of tests for SARS-CoV-2, highlight gaps in current diagnostic capacity, and propose potential solutions.","Ann Intern Med","Cheng, Matthew P","Papenburg, Jesse","Desjardins, Michael","Kanjilal, Sanjat","Quach, Caroline","Libman, Michael","Dittrich, Sabine","Yansouni, Cedric P","32282894"],"abstract":["Diagnostic testing to identify persons infected with severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) infection is central to control the global pandemic of COVID-19 that began in late 2019. In a few countries, the use of diagnostic testing on a massive scale has been a cornerstone of successful containment strategies. In contrast, the United States, hampered by limited testing capacity, has prioritized testing for specific groups of persons. Real-time reverse transcriptase polymerase chain reaction-based assays performed in a laboratory on respiratory specimens are the reference standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging. Although excellent tools exist for the diagnosis of symptomatic patients in well-equipped laboratories, important gaps remain in screening asymptomatic persons in the incubation phase, as well as in the accurate determination of live viral shedding during convalescence to inform decisions to end isolation. Many affluent countries have encountered challenges in test delivery and specimen collection that have inhibited rapid increases in testing capacity. These challenges may be even greater in low-resource settings. Urgent clinical and public health needs currently drive an unprecedented global effort to increase testing capacity for SARS-CoV-2 infection. Here, the authors review the current array of tests for SARS-CoV-2, highlight gaps in current diagnostic capacity, and propose potential solutions."],"journal":"Ann Intern Med","authors":["Cheng, Matthew P","Papenburg, Jesse","Desjardins, Michael","Kanjilal, Sanjat","Quach, Caroline","Libman, Michael","Dittrich, Sabine","Yansouni, Cedric P"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282894","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.7326/M20-1301","locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491459731457,"score":210.74663},{"pmid":32466458,"title":"Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2.","text":["Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2.","The recent outbreak of the Coronavirus disease 2019 (COVID-19) has quickly spread worldwide since its discovery in Wuhan city, China in December 2019. A comprehensive strategy, including surveillance, diagnostics, research, clinical treatment, and development of vaccines, is urgently needed to win the battle against COVID-19. The past three unprecedented outbreaks of emerging human coronavirus infections at the beginning of the 21st century have highlighted the importance of readily available, accurate, and rapid diagnostic technologies to contain emerging and re-emerging pandemics. Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) based assays performed on respiratory specimens remain the gold standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging with high sensitivity and specificity as well. Even though excellent techniques are available for the diagnosis of symptomatic patients with COVID-19 in well-equipped laboratories; critical gaps still remain in screening asymptomatic people who are in the incubation phase of the virus, as well as in the accurate determination of live viral shedding during convalescence to inform decisions for ending isolation. This review article aims to discuss the currently available laboratory methods and surveillance technologies available for the detection of COVID-19, their performance characteristics and highlight the gaps in current diagnostic capacity, and finally, propose potential solutions. We also summarize the specifications of the majority of the available commercial kits (PCR, EIA, and POC) for laboratory diagnosis of COVID-19.","Viruses","Younes, Nadin","Al-Sadeq, Duaa W","Al-Jighefee, Hadeel","Younes, Salma","Al-Jamal, Ola","Daas, Hanin I","Yassine, Hadi M","Nasrallah, Gheyath K","32466458"],"abstract":["The recent outbreak of the Coronavirus disease 2019 (COVID-19) has quickly spread worldwide since its discovery in Wuhan city, China in December 2019. A comprehensive strategy, including surveillance, diagnostics, research, clinical treatment, and development of vaccines, is urgently needed to win the battle against COVID-19. The past three unprecedented outbreaks of emerging human coronavirus infections at the beginning of the 21st century have highlighted the importance of readily available, accurate, and rapid diagnostic technologies to contain emerging and re-emerging pandemics. Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) based assays performed on respiratory specimens remain the gold standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging with high sensitivity and specificity as well. Even though excellent techniques are available for the diagnosis of symptomatic patients with COVID-19 in well-equipped laboratories; critical gaps still remain in screening asymptomatic people who are in the incubation phase of the virus, as well as in the accurate determination of live viral shedding during convalescence to inform decisions for ending isolation. This review article aims to discuss the currently available laboratory methods and surveillance technologies available for the detection of COVID-19, their performance characteristics and highlight the gaps in current diagnostic capacity, and finally, propose potential solutions. We also summarize the specifications of the majority of the available commercial kits (PCR, EIA, and POC) for laboratory diagnosis of COVID-19."],"journal":"Viruses","authors":["Younes, Nadin","Al-Sadeq, Duaa W","Al-Jighefee, Hadeel","Younes, Salma","Al-Jamal, Ola","Daas, Hanin I","Yassine, Hadi M","Nasrallah, Gheyath K"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32466458","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/v12060582","keywords":["covid-19","sars-cov-2","diagnostic challenges","molecular testing","serology","viruses"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Prevention"],"weight":1,"_version_":1668420887292936193,"score":183.59065},{"pmid":32401064,"title":"CRISPR-Cas Systems Based Molecular Diagnostic Tool for Infectious Diseases and Emerging 2019 Novel Coronavirus (COVID-19) Pneumonia.","text":["CRISPR-Cas Systems Based Molecular Diagnostic Tool for Infectious Diseases and Emerging 2019 Novel Coronavirus (COVID-19) Pneumonia.","Emerging infectious diseases, the persistent potential for destabilizing pandemics, remain a global threat leading to excessive morbidity and mortality. The current outbreak of pneumonia caused by 2019 novel coronavirus (COVID-19) illustrated difficulties in lack of effective drugs for treatment. Accurate and rapid diagnostic tools are essential for early recognition and treatment of infectious diseases, allowing timely implementation of infection control, improved clinical care and other public health measures to stop the spread of the disease. CRISPR-Cas technology speed up the development of infectious disease diagnostics with high rapid and accurate. In this review, we summarize current advance regarding diverse CRISPR-Cas systems, including CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13, in the development of fast, accurate and portable diagnostic tests and highlight the potential of CRISPR-Cas13 in COVID-19 Pneumonia and other emerging infectious diseases diagnosis.","J Drug Target","Xiang, Xiaohong","Qian, Keli","Zhang, Zhen","Lin, Fengyun","Xie, Yang","Liu, Yang","Yang, Zongfa","32401064"],"abstract":["Emerging infectious diseases, the persistent potential for destabilizing pandemics, remain a global threat leading to excessive morbidity and mortality. The current outbreak of pneumonia caused by 2019 novel coronavirus (COVID-19) illustrated difficulties in lack of effective drugs for treatment. Accurate and rapid diagnostic tools are essential for early recognition and treatment of infectious diseases, allowing timely implementation of infection control, improved clinical care and other public health measures to stop the spread of the disease. CRISPR-Cas technology speed up the development of infectious disease diagnostics with high rapid and accurate. In this review, we summarize current advance regarding diverse CRISPR-Cas systems, including CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13, in the development of fast, accurate and portable diagnostic tests and highlight the potential of CRISPR-Cas13 in COVID-19 Pneumonia and other emerging infectious diseases diagnosis."],"journal":"J Drug Target","authors":["Xiang, Xiaohong","Qian, Keli","Zhang, Zhen","Lin, Fengyun","Xie, Yang","Liu, Yang","Yang, Zongfa"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32401064","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1080/1061186X.2020.1769637","keywords":["covid-19","crispr-cas","diagnostics","infectious diseases"],"locations":["Pneumonia"],"topics":["Diagnosis"],"weight":1,"_version_":1666714494696423424,"score":176.79926},{"pmid":32292623,"pmcid":"PMC7102540","title":"Recent advances and perspectives of nucleic acid detection for coronavirus.","text":["Recent advances and perspectives of nucleic acid detection for coronavirus.","The recent pneumonia outbreak caused by a novel coronavirus (SARS-CoV-2) in Chinais posing a great threat to global public health. Therefore, rapid and a accurate identification of pathogenic viruses plays a vital role in selecting appropriate treatments, saving people's lives and preventing epidemics. It is important to establish a quick standard diagnostic test for the detection of the infectious disease (COVID-19) to prevent subsequent secondary spread. Polymerase chain reaction (PCR) is regarded as a gold standard test for the molecular diagnosis of viral and bacterial infections with high sensitivity and specificity. Isothermal nucleic acid amplification is considered to be a highly promising candidate method due to its fundamental advantage in quick procedure time at constant temperature without thermocycler operation. A variety of improved or new approaches also have been developed. This review summarizes the currently available detection methods for coronavirus nucleic acid. It is anticipated that this will assist researchers and clinicians in developing better techniques for timely and effective detection of coronavirus infection.","J Pharm Anal","Shen, Minzhe","Zhou, Ying","Ye, Jiawei","Abdullah Al-Maskri, Abdu Ahmed","Kang, Yu","Zeng, Su","Cai, Sheng","32292623"],"abstract":["The recent pneumonia outbreak caused by a novel coronavirus (SARS-CoV-2) in Chinais posing a great threat to global public health. Therefore, rapid and a accurate identification of pathogenic viruses plays a vital role in selecting appropriate treatments, saving people's lives and preventing epidemics. It is important to establish a quick standard diagnostic test for the detection of the infectious disease (COVID-19) to prevent subsequent secondary spread. Polymerase chain reaction (PCR) is regarded as a gold standard test for the molecular diagnosis of viral and bacterial infections with high sensitivity and specificity. Isothermal nucleic acid amplification is considered to be a highly promising candidate method due to its fundamental advantage in quick procedure time at constant temperature without thermocycler operation. A variety of improved or new approaches also have been developed. This review summarizes the currently available detection methods for coronavirus nucleic acid. It is anticipated that this will assist researchers and clinicians in developing better techniques for timely and effective detection of coronavirus infection."],"journal":"J Pharm Anal","authors":["Shen, Minzhe","Zhou, Ying","Ye, Jiawei","Abdullah Al-Maskri, Abdu Ahmed","Kang, Yu","Zeng, Su","Cai, Sheng"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292623","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jpha.2020.02.010","keywords":["coronavirus","isothermal nucleic acid amplification-based methods","microarray-based methods","nucleic acid detection","pcr-based methods"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494433492992,"score":166.6672}]}